Wei Liwei, Wang Fubo, Yang Guanglin, Liao Naikai, Cui Zelin, Chen Hao, Zhao Qiyue, Qin Min, Cheng Ji-Wen
Department of Urology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.
Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China.
Transl Cancer Res. 2024 Aug 31;13(8):4085-4095. doi: 10.21037/tcr-24-561. Epub 2024 Aug 27.
More muscle-invasive bladder cancer (MIBC) patients are now eligible for bladder-preserving therapy (BPT), underscoring the need for precision medicine. This study aimed to identify prognostic predictors and construct a predictive model among MIBC patients who undergo BPT.
Data relating to MIBC patients were obtained from the Surveillance, Epidemiology and End Results (SEER) database from 2004 to 2016. Eleven features were included to establish multiple models. The predictive effectiveness was assessed using receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA) and clinical impact curve (CIC). SHapley Additive exPlanations (SHAP) were used to explain the impact of features on the predicted targets.
The ROC showed that Catboost and Random Forest (RF) obtained better predictive discrimination in both 3- and 5-year models [test set area under curves (AUC) =0.80 and 0.83, respectively]. Furthermore, Catboost showed better performance in calibration plots, DCA and CIC. SHAP analysis indicated that age, M stage, tumor size, chemotherapy, T stage and gender were the most important features in the model for predicting the 3-year cancer-specific survival (CSS). In contrast, M stage, age, tumor size and gender as well as the N and T stages were the most important features for predicting the 5-year CSS.
The Catboost model exhibits the highest predictive performance and clinical utility, potentially aiding clinicians in making optimal individualized decisions for MIBC patients with BPT.
现在更多的肌层浸润性膀胱癌(MIBC)患者符合保膀胱治疗(BPT)的条件,这凸显了精准医学的必要性。本研究旨在确定MIBC患者接受BPT后的预后预测因素并构建预测模型。
从2004年至2016年的监测、流行病学和最终结果(SEER)数据库中获取与MIBC患者相关的数据。纳入11个特征以建立多个模型。使用受试者工作特征(ROC)曲线、校准图、决策曲线分析(DCA)和临床影响曲线(CIC)评估预测有效性。使用SHapley加性解释(SHAP)来解释特征对预测目标的影响。
ROC显示,Catboost和随机森林(RF)在3年和5年模型中均获得了更好的预测区分度[测试集曲线下面积(AUC)分别为0.80和0.83]。此外,Catboost在校准图、DCA和CIC方面表现更好。SHAP分析表明,年龄、M分期、肿瘤大小、化疗、T分期和性别是预测3年癌症特异性生存(CSS)模型中最重要的特征。相比之下,M分期、年龄、肿瘤大小和性别以及N和T分期是预测5年CSS的最重要特征。
Catboost模型表现出最高的预测性能和临床实用性,可能有助于临床医生为接受BPT的MIBC患者做出最佳的个体化决策。